AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06733077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait with cueing wearable device and neuro-ocular performance
Description: Participants will be invited to participate in the following sequential phases. Participants can participate in Phases as selected. Control participants will not be invited to Phase 4.~Phase 1. Lab testing \[2 hours\] Validation study of digital technology measures MachineMD and gaitQ to criterion metric of UPDRS.~Phase 2. home/community testing \[2 weeks daily\] Determine feasibility of daily measuring in the home of gaitQ to determine usability, acceptability, and day to day variability of measurement metrics and to determine concurrent validation of home metric to lab metrics to determine, reliability, concurrent validity of change, minimal detectable change and criterion validation to lab-based measures.~Phase 3. Lab retesting \[2 hours\] see Phase 1~Phase 4. Home/community intervention \[2 weeks\] Determine the potential for effect of the gaitQ vibration intervention from a 2-week exposure in the home.
Study NCT06722170 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EH002 administration
Description: EH002 was administered into one or both ears via intracochlear injection.
Study NCT06732895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
Study NCT06732895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Study NCT06750705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PechaKucha
Description: The PechaKucha format consists of 20 slides, each displayed for 20 seconds, focusing on vital signs measurement skills. The method emphasizes a fast-paced, engaging, and visual learning experience designed to enhance retention and improve students' practical knowledge and skills in measuring vital signs.
Study NCT06750705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PowerPoint
Description: The PowerPoint presentation will cover the same vital signs measurement content but in a more conventional, linear format. The intervention will aim to reinforce students' understanding of vital signs through text and images, with a slower pace compared to the PechaKucha method.
Study NCT06751836 — intervention group
Intervention type: OTHER
Intervention: Infection and no infection
Description: No intervention apart from the dengue infection
Study NCT06753864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T)
Description: Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
Study NCT05486533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with LI4 points and continue P6 and LI11 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
Study NCT06753864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R)
Description: Abaloparatide injection (Tymlos®), specification :3120 μg/1.56 ml(2000 μg/ml), drug information is subject to actual supply, provided by Qilu Pharmaceutical Co., LTD. The reference preparations for the subjects were all from the same batch number.
Study NCT06754384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
Description: Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ）
Study NCT06754384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
Description: Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
Study NCT06754384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
Description: High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
Study NCT06754384 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
Description: EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
Study NCT06754384 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for ages 6-12 years)
Description: placebo (for ages 6-12 years)
Study NCT06756126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 subcutaneous injection
Study NCT06753682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Plant Based Diet
Description: Registered Dietician will assist in modifying the patient's diet
Study NCT06753487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofacial Release
Description: Manual Myofascial Release:~Control group will receive 3- 5 repetitions of Manual Myofascial Release in Piriformis muscle i.e giving ischemic pressure on muscle directly for 90 secs and then release.
Study NCT06753487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facilitated positional release technique
Description: FPRT:~Treatment group will receive 5 repetitions of FACILITATED POSITIONAL RELEASE technique i.e applying pressure over tender area of muscle while maintaining specific postion
Study NCT06751849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
Study NCT06751849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Study NCT06751849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06269393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
Study NCT06269393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBI311
Description: IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
Study NCT05131373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG101 - Experimental 1
Description: C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
Study NCT05131373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORG101PL - Placebo 1
Description: Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
Study NCT06753110 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OPRA transhumeral
Description: Skeletal anchorage of amputation prostheses.
Study NCT04711889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin is taken three times a day.
Study NCT04711889 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Blank control
Description: Blank control
Study NCT04648189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
Study NCT04649866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: plethysmography
Description: Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline
Study NCT04649866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: plethysmography
Description: Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline
Study NCT06487455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH7485
Description: SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
Study NCT05974449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Lactobacillus capsules
Description: This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
Study NCT04840550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Study NCT04840550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 25 mg
Description: Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Study NCT05741879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified exercise training
Description: Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s).
Study NCT05741879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
Study NCT05240105 — intervention group
Intervention type: OTHER
Intervention: no intervention, purely observational
Description: There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.
Study NCT05042778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
Study NCT04937153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV) once every 21 days.
Study NCT04937153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV once every 21 days.
Study NCT05480150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets
Description: Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
Study NCT05480150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Tablets
Description: Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
Study NCT05480150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
Study NCT04731779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
Study NCT04731779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil
Study NCT04838262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Stressors
Description: Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
Study NCT06018480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: The supplementation is the intervention.
Study NCT06018480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: Placebo to Creatine Monohydrate
Study NCT03141424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapering of inhaled corticosteroid (ICS) treatment
Description: Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
Study NCT06579742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Conscious Beyond Collagen
Description: Participants in the experimental arm will take 1 scoop (10.4 g) of Live Conscious Beyond Collagen supplement mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
Study NCT06579742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo comparator arm will take 1 scoop (10.4 g) of the placebo product (Maltodextrin) mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
Study NCT06009081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postural exercise
Description: The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
Study NCT06009081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
Study NCT06580483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amalgam restoration
Description: An abutment tooth is restored on a side by amalgam plug
Study NCT06366724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)
Study NCT06366724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)
Study NCT06366724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)
Study NCT06366724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)
Study NCT06580483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nano-composite
Description: An abutment tooth is restored on a side by nano-composite
Study NCT05449951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
Study NCT05449951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sustained stretching
Description: sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
Study NCT05968651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Single acute administration of 24 international units (IU) oxytocin
Study NCT05968651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Single acute administration of 24 international units (IU) oxytocin
Study NCT06072378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value-manipulation
Description: During the decision-making task, different choices are assigned different values probabilistically.
Study NCT05130970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garadacimab
Description: Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
Study NCT05130970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received a matching placebo IV loading dose, followed by 3 SC doses.
Study NCT05620823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study NCT05620823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; Tablet
Study NCT06369259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given by PO
Study NCT06369259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV
Study NCT06369259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Given by PO
Study NCT06126783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI311
Description: The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
Study NCT05703854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.70/IL15-transduced CB-derived NK cells
Description: Given by IV (vein)
Study NCT05703854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)
Study NCT05703854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study NCT06576362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
Description: Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
Study NCT05972551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Subcutaneous (SC) injection
Study NCT05972551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate
Description: Administration determined by investigator according to the local standard of care